1. Home
  2. ALEC

as 04-01-2025 2:30pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.

Founded: 2013 Country:
United States
United States
Employees: N/A City: SOUTH SAN FRANCISCO
Market Cap: 162.6M IPO Year: 2019
Target Price: $4.10 AVG Volume (30 days): 565.4K
Analyst Decision: Buy Number of Analysts: 7
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.23 EPS Growth: N/A
52 Week Low/High: $1.20 - $6.78 Next Earning Date: 05-07-2025
Revenue: $100,558,000 Revenue Growth: 3.60%
Revenue Growth (this year): -59.27% Revenue Growth (next year): 40.79%

ALEC Daily Stock ML Predictions

SELLHOLDBUYas of 5 hours ago

Stock Insider Trading Activity of Alector Inc. (ALEC)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Rosenthal Arnon ALEC Chief Executive Officer Mar 3 '25 Sell $1.47 40,330 $59,176.21 2,466,744
Romano Gary ALEC Chief Medical Officer Mar 3 '25 Sell $1.47 16,306 $23,927.42 332,977
GRASSO MARC ALEC Chief Financial Officer Mar 3 '25 Sell $1.47 18,091 $26,546.73 312,560
Kenkare-Mitra Sara ALEC President and Head of R&D Mar 3 '25 Sell $1.47 29,073 $42,661.72 536,142

Share on Social Networks:

By browsing this website, you accept our Privacy Policy & Terms of Use